ID: ALA572124

Max Phase: Preclinical

Molecular Formula: C13H11BrN2O5

Molecular Weight: 355.14

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(Cc2nc(O)c(O)c(C(=O)O)n2)cc1Br

Standard InChI:  InChI=1S/C13H11BrN2O5/c1-21-8-3-2-6(4-7(8)14)5-9-15-10(13(19)20)11(17)12(18)16-9/h2-4,17H,5H2,1H3,(H,19,20)(H,15,16,18)

Standard InChI Key:  LQQYBZYFFRDXNT-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 355.14

Molecular Weight (Monoisotopic): 353.9851

AlogP: 1.95

#Rotatable Bonds: 4

Polar Surface Area: 112.77

Molecular Species: ACID

HBA: 6

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 0.07

CX Basic pKa: 5.02

CX LogP: 1.47

CX LogD: -0.01

Aromatic Rings: 2

Heavy Atoms: 21

QED Weighted: 0.77

Np Likeness Score: -0.48

References

1. Kirschberg TA, Balakrishnan M, Squires NH, Barnes T, Brendza KM, Chen X, Eisenberg EJ, Jin W, Kutty N, Leavitt S, Liclican A, Liu Q, Liu X, Mak J, Perry JK, Wang M, Watkins WJ, Lansdon EB..  (2009)  RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information.,  52  (19): [PMID:19791799] [10.1021/jm900597q]

2. Gao P, Cheng X, Sun L, Song S, Álvarez M, Luczkowiak J, Pannecouque C, De Clercq E, Menéndez-Arias L, Zhan P, Liu X..  (2019)  Design, synthesis and biological evaluation of 3-hydroxyquinazoline-2,4(1H,3H)-diones as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and integrase.,  27  (17): [PMID:31324562] [10.1016/j.bmc.2019.07.011]

Source

Source(1):

• Scientific Literature